ArticleIrish journal of medical science2026
The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWomen with polycystic ovary syndrome (PCOS) have a higher prevalence of obesity, which negatively impacts health. Guidelines suggest that GLP1 Receptor Agonists could be considered but highlight a lack of evidence for treatment in PCOS. Reducing body weight by as little as 5% has significant benefits in women with PCOS.
aimsThe aim of this retrospective study was to analyse the metabolic impact of semaglutide use in routine clinical practice in obese women with PCOS.
methodsData were collected on 58 women with PCOS and obesity attending reproductive endocrinology clinics and prescribed semaglutide therapy for > 6 months.
resultsMean age was 34.7 ± 6.8 years. Median duration of GLP1 agonist therapy was 12(7-17) months. Mean weight loss was 12.6 ± 9.6 kg (11.4% total body weight, p < 0.0001). 81% of women lost > 5% of their total body weight. Mean BMI reduced from 40.7 ± 6.3 to 36.2 ± 6.7 kg/m² (p < 0.0001). Mean systolic blood pressure reduced by 6.3mmHg (p = 0.012). Median HbA1C reduced from 35.3 (32.8-38.3) to 33 (31-35) mmol/mol (p = 0.0014). Mean total cholesterol reduced from 4.8 ± 0.9 mmol/L to 4.45 ± 0.91 mmol/L, p = 0.03. 50% of those with oligomenorrhoea reported subjective improvement in their menstrual cycles. 33% of those with acne and 29% of those with hirsutism reported improvements in their symptoms.
conclusionsIn this real-world analysis of clinical practice, semaglutide use in obese women with PCOS was associated with significant weight loss, reduced systolic blood pressure, cholesterol and HbA1C.
Indexed as
Identifiers
41283946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.